Gardiquimod

• UNSPSC Description:

  Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10?μM[1][2].

• Target Antigen:

  HIV; Toll-like Receptor (TLR)

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/gardiquimod.html

• Purity:

  99.91

• Solubility:

  DMF : ≥ 20 mg/mL|DMSO : ≥ 20 mg/mL|Ethanol : ≥ 12 mg/mL

• Smiles:

  OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N

• Molecular Weight:

  313.40

• References & Citations:

  [1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18.|[2]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1020412-43-4